Chinese SLE Treatment and Research Group (CSTAR) Registry: Prevalence and Risk Factors for Chronic Scarring Alopecia in Patients with Systemic Lupus Erythematosus

    August 2020 in “ Research Square (Research Square) ”
    Yirong Xiang, Mengtao Li, Hui Luo, Yanhong Wang, Xinwang Duan, Cheng Zhao, Zhan Feng, Zhenbiao Wu, Hongbin Li, Min Yang, Jian Xu, Wei Wei, Lijun Wu, Hanxiao You, Junyan Qian, Xiaoxi Yang, Can Huang, Jiuliang Zhao, Qian Wang, Xiaomei Leng, Xinping Tian, Yan Zhao, Xiaofeng Zeng
    Studysummary This study reported that 7.80% of systemic lupus erythematosus patients experienced scarring alopecia, with mucocutaneous lesions and certain autoantibodies identified as risk factors, and some organ involvements and immunosuppressants as protective factors.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    The study investigated the prevalence and risk factors for chronic scarring alopecia in patients with systemic lupus erythematosus (SLE) using data from the Chinese SLE Treatment and Research Group (CSTAR) registry. Among 4,792 SLE patients, 374 (7.80%) experienced scarring alopecia. Risk factors identified included mucocutaneous lesions, high SLICC/ACR-DI scores, and positive anti-Sm antibodies. Conversely, renal and cardio-respiratory involvements, as well as treatment with immunosuppressants, were found to be protective factors. The study concluded that active treatment strategies should be implemented to prevent the occurrence of scarring alopecia in SLE patients.
    Discuss this study in the Community →

    Research cited in this study

    3 / 3 results